Abstract:OBJECTIVE To compare the prognoses of non-small cell lung cancer patients based respectively on the 6th-Edition Staging System for NSCLC (the 6th-Edition Staging System) and the new staging system by the International Association for the Study of Lung Cancer (IASLC) (new staging system). METHODS Data were collected from 136 operated NSCLC patients from Sep. 2003 through Oct. 2007. Those data were staged based respectively on the 6th-Edition Staging System and the new staging system. The 2-year no-recurrence survival rate was calculated, and life span was analyzed using the Kaplan-Meier method of SPSS 13.0 software. RESULTS (1) In this series, using the 6th-Edition Staging System, there were 56, 23, 53 and 4 patients in stage I, stage II, stage III and stage IV respectively; using the new staging system, there were 50, 31, 54 and 1 patients in stage I, stage II, stage III and stage IV respectively. There were 6 patients in stage I according to the 6th-Edition Staging System who had become 6 patients in stage II according to the new staging system, 1 patient in stage II 1 in stage III, 3 patients in stage III 3 in stage II, 1 patient in stage III 1 in stage IV, and 4 patients in stage IV 4 in stage III. (2) According to the 6th-Edition Staging System, the 2-year no-recurrence survival rates for Ia, Ib, IIa, IIb,IIIa, IIIb and IV were 95.0%, 83.3%, 100.0%, 63.6%, 52.1%, 80.0% and 50.0% respectively, and according to the new staging system, the 2-year cumulative survival rates for I a, Ib, IIa, IIb, IIIa, IIIb and IV were 95.5%, 89.3%, 68.4%, 63.6%, 52.8%, 50.0% and 0.0% respectively. After Chi square analysis, there was no distinguished difference between the 2 staging systems for the 2-year cumulative survival rate. (3) According to the 6th-Edition Staging System, the difference between the no-recurrence rate of stage I and stage II was not statistically significant (P = 0.232), and the difference between the no-recurrence rates of stage II and III was statistically significant(P = 0.023); according to the new staging system, the difference between the no-recurrence rates of stage I and stage II as well as between those of stage II and stage III were both statistically significant (P = 0.023 and 0.014 respectively). (4) The differences between the no-recurrence rates of the patients on the two sides, above and below the tumor maximum diameter cutpoint 2 cm, as well as the cutpoint 5 cm were statistically significant (P = 0.025; P = 0.023). CONCLUSION The new staging system by NSCLC has better staging specificity than the 6th-Edition Staging System and could be used for Chinese patients.

[Application of the 2007 Lung Cancer Staging System by International Association for the Study of Lung Cancer].

Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis

Comparison of Value for Predicting Prognosis between the 6th and 7th Editions of TNM Staging System in Gastric Cancer Patients

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small-cell Lung Cancer

A Comparison Between the Chinese 2008 and the 7th Edition AJCC Staging Systems for Nasopharyngeal Carcinoma

Comparison of the 7th and 6th edition AJCC TNM staging systems for gastric cancer: analysis of prognosis in a retrospective review of 918 patients at a single institution in China

Evaluation of the 7th Edition of the TNM Classification for Lung Cancer at a Single Institution.

Comparison of the TNM9th and 8th editions for localized and locally advanced anal squamous cell carcinoma treated nonsurgically and proposal of a new stage grouping system

The 8th Edition of the American Joint Committee on Cancer Tumor-Node-metastasis Staging System for Gastric Cancer is Superior to the 7th Edition: Results from a Chinese Mono-Institutional Study of 1663 Patients.

Comparative Effectiveness of the Revised American Joint Committee on Cancer Staging System

Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.

A Comparison the 7th and 8th Edition AJCCTNM Staging Systems for Predicting Disease Free Survival Time after Surgery in Primary Liver Cancer Patients

Comparison of the Chinese 2008 and the 7th Edition Ajcc Staging Systems for Nasopharyngeal Carcinoma

The evolution of the nasopharyngeal carcinoma staging system over a 10-year period: implications for future revisions

New N Staging System of Penile Cancer Provides a Better Reflection of Prognosis

Multivariate Survival Analysis of Patients with Stage I NSCLC

The Revision of 8th Edition TNM Stage Criteria is More Accurate in Prediction Postoperative Survival for SCLC Patients

Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis.

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Comparison of the Survival Difference Between AJCC 6th and 7th Editions for Gastric Cancer Patients.

Validation of the 9th edition of the TNM staging system for non-small cell lung cancer with lobectomy in stage IA–IIIA